United Capital Financial Advisors LLC Acquires Shares of 443 argenx SE (NASDAQ:ARGX)

United Capital Financial Advisors LLC acquired a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 443 shares of the company's stock, valued at approximately $272,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC lifted its holdings in argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after purchasing an additional 20 shares during the last quarter. SG Americas Securities LLC grew its position in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after purchasing an additional 21 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares in the last quarter. Dynasty Wealth Management LLC lifted its holdings in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after buying an additional 22 shares in the last quarter. Finally, Choreo LLC boosted its position in shares of argenx by 4.4% in the fourth quarter. Choreo LLC now owns 551 shares of the company's stock valued at $342,000 after acquiring an additional 23 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Robert W. Baird raised their price target on shares of argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. Citigroup lifted their price target on argenx from $681.00 to $796.00 and gave the company a "buy" rating in a research report on Thursday, April 17th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, Guggenheim lifted their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $699.28.

argenx Stock Up 2.4 %

Shares of argenx stock traded up $14.25 on Friday, hitting $614.76. The stock had a trading volume of 215,836 shares, compared to its average volume of 308,133. argenx SE has a one year low of $352.77 and a one year high of $678.21. The stock's 50-day simple moving average is $598.28 and its two-hundred day simple moving average is $609.01. The stock has a market cap of $37.54 billion, a price-to-earnings ratio of -698.59 and a beta of 0.60.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.